Abstract 431P
Background
Glioma is one of the most common types of tumor of the central nervous system with high morbidity and mortality. Based on this fact that the prognosis of patients with high- grade glioma is poor, it is very important to develop new diagnostic and therapeutic strategies covering more efficient methods and drugs. Recent studies have demonstrated that Long non-coding RNAs (lncRNAs) may act as potential inducers or suppressors of numerous types of tumors including glioma. Besides, there are more expression of lncRNAs than coding mRNAs and miRNAs in specific tissues.In this study we evaluated two lncRNAs including MEG3 and MDC1-AS1 which seemed to be involved in the initiation and progression of high grade Gliomas.
Methods
The expression of lncRNAs were studied on 150 paraffin tissue block samples of Iranian participants, including 37 samples of low-grade gliomas(I&II), 58 samples of high grade glioma (III& IV) and 95 samples of non-tumoral tissues. After RNA extraction and complementary DNA synthesis(cDNA), probe-based (Taqman) Real-time PCR were used to evaluate lncRNAs expression level followed by statistical analizing.
Results
Our analysis, indicates that lncRNAs including MEG3 and MDC-AS1 are down-regulated (p =0.001) in high grade glioma tumors (grade III & IV) in comparison to low grade gliomas (grade I and II) and non-tumoral tissues.
Conclusions
The results show that there are critical expression differences i n MEG3 and MDC1-AS1 lncRNAs as tumor suppressor genes between high and low-grade gliomas. Comprising with other reports, it could be assumed that expression of MEG3 and MDC1-AS1 lncRNAs may serve as potential biomarkers and also therapeutic targets for detection and treatment of glioma tumors. Key words: Quantitative, lncRNAs, glioma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Arash Moradi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
338P - Vitamin E in the treatment of chemotherapy and radiation-induced mucositis: A meta-analysis of randomized controlled trials
Presenter: Michelle Joane Alcantara
Session: e-Poster Display Session
339P - Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation: A phase III study
Presenter: Vikas Talreja
Session: e-Poster Display Session
340P - Omega-3 fatty acids for cancer cachexia in advanced non-small cell lung cancer: A meta-analysis
Presenter: Alfredo Chua
Session: e-Poster Display Session
341P - Relationship between muscle mass and quality of life in breast cancer patients who underwent chemotherapy
Presenter: Andree Kurniawan
Session: e-Poster Display Session
342P - Comparison of 0.25 mg versus 0.75 mg of palonosetron in combination with aprepitant and dexamethasone for prevention of chemotherapy-induced nausea and vomiting following cisplatin-containing chemotherapy in patients with esophageal cancer
Presenter: Satoshi Horasawa
Session: e-Poster Display Session
343P - Head-to-head comparison of palonosetron versus granisetron for prevention of chemotherapy induced nausea and vomiting: Systematic review and meta-analysis
Presenter: Chin-Hung Hsu
Session: e-Poster Display Session
344P - Single-centre analysis of anti-resorptive agent-related osteonecrosis of the jaw in lung cancer patients
Presenter: Kohei Fujita
Session: e-Poster Display Session
345P - Thromboembolic events in brain tumour patients on bevacizumab
Presenter: Gunjesh Singh
Session: e-Poster Display Session
346P - Occurence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer: A hospital-based assessment in Indonesia
Presenter: Susanna Hutajulu
Session: e-Poster Display Session
347P - Histamine blockade with loratadine for prevention of granulocyte-colony stimulating factor (G-CSF)-associated bone pain: A meta-analysis
Presenter: Mel Valerie Ordinario
Session: e-Poster Display Session